MASLD Increases Risk of Youth-Onset Type 2 Diabetes in Children with Obesity
HCPLive
OCTOBER 15, 2024
Study findings showed children with both obesity and MASLD have a greater risk of youth-onset type 2 diabetes than those with obesity alone.
Cardiorenal effects of therapies for type 2 diabetes and obesity
The British Journal of Cardiology
OCTOBER 8, 2024
Sodium-glucose cotransporter type 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists are established glucose-lowering and weight-lowering agents used in the management of type 2 diabetes mellitus and obesity.
Obesity 
52
52 
Cardiometabolic benefits of fenofibrate in heart failure related to obesity and diabetes
Cardiovascular Diabetology
SEPTEMBER 15, 2024
Background Heart failure (HF) is a serious and common condition affecting millions of people worldwide, with obesity being a major cause of metabolic disorders such as diabetes and cardiovascular disease. In addition, we investigated the beneficial effects of fenofibrate on HF hospitalization. During the 4.22-year
Obesity 52
52 
Popular Diabetes Drug Class Lowered Risk of 10 Obesity-Associated Cancers
Med Page Today
JULY 5, 2024
(MedPage Today) -- GLP-1 receptor agonists lowered the risk of several obesity-associated cancers, a retrospective analysis of electronic health records suggested. Compared with insulin, GLP-1s were associated with a lower risk for developing.
Obesity 112
112 
Diabetes Dialogue: ADA Introduces Obesity Association, with Robert Gabbay, MD, PhD
HCPLive
JUNE 23, 2024
In the special on-site ADA 2024 episode, hosts are joined by the ADA's Chief Scientific and Medical Officer Robert Gabbay, MD, PhD, to discuss the newly formed Obesity Association.
Obesity 83
83 
Babies born to women consuming a high fat, sugary diet at greater risk of cardiovascular disease and diabetes in later life
Science Daily - Heart Disease
SEPTEMBER 13, 2024
Babies born to pregnant women with obesity are more likely to develop heart problems and diabetes as adults due to fetal damage caused by the high-fat, high-energy diet of their mother.
Diet 128
128 
Have We Turned The Tide On Obesity?
Dr. Paddy Barrett
OCTOBER 11, 2024
Obesity is one of the world’s biggest health crisis and only seems to be getting worse. For over 50 years, the rates of obesity have continued to rise worldwide 1. The most recent data on obesity has shown a decline for the first time in a very long time. Between 2020 and 2023, the rates of obesity dropped by about 2% 2.
Obesity 52
52 
Childhood stress linked to higher risk of high blood pressure, obesity, diabetes in adults
American Heart News - Heart News
JANUARY 17, 2024
Research Highlights: Consistently high scores of perceived stress during adolescence through adulthood may contribute to worse cardiometabolic health including obesity in young adults. Researchers suggest the adoption of healthy coping strategies.
Obesity 118
118 
New Study Finds Tirzepatide Use Lowered Blood Pressure in Patients with Obesity
HCPLive
FEBRUARY 5, 2024
Tirzepatide, a dual GLP-1/GIP agonist approved for diabetes and obesity, was associated with significant blood pressure reductions in an analysis of the SURMOUNT-1 trial.
Blood Pressure 116
116 
Semaglutide Treatment Effect in People With Obesity and Heart Failure With Preserved Ejection Fraction and Diabetes Mellitus
American College of Cardiology
APRIL 6, 2024
The goal of the STEP-HFpEF DM trial was to compare the safety and efficacy of semaglutide among patients with obesity-related heart failure with preserved ejection fraction (HFpEF) and type 2 diabetes mellitus (DM).
Exploring Obesity and the Latest Advances in Weight Loss Drugs during Healthy Weight Week
Cardiometabolic Health Congress
JANUARY 3, 2024
In today’s society, the prevalence of obesity has become a significant concern. have obesity, and this rate has increased by more than 10 percentage points in the past two decades. Understanding the prevalence of obesity is crucial in comprehending why events like Healthy Weight Week are essential. of adults in the U.S.
Obesity 97
97 
Nonlinear association between atherogenic index of plasma and type 2 diabetes mellitus in overweight and obesity patients: evidence from Chinese medical examination data
Cardiovascular Diabetology
JUNE 28, 2024
The atherogenic index of plasma (AIP) is closely associated with the onset of diabetes, with obesity being a significant risk factor for type 2 diabetes mellitus (T2DM). However, the association between the AI.
Obesity 52
52 
Childhood stress linked to higher risk of high blood pressure, obesity, diabetes in adults
Science Daily - Heart Disease
JANUARY 17, 2024
Young adults who reported higher stress as adolescents were more likely to have high blood pressure, obesity and other cardiometabolic risk factors as adults, finds new study.
Blood Pressure 108
108 
The double burden: type 1 diabetes and heart failure—a comprehensive review
Cardiovascular Diabetology
FEBRUARY 11, 2024
Heart failure (HF) is increasing at an alarming rate, primary due to the rising in aging, obesity and diabetes. Notably, individuals with type 1 diabetes (T1D) face a significantly elevated risk of HF, leading.
Heart Failure 111
111 
Obesity Indicators Linked to Gout Risk in Patients with Type 2 Diabetes
HCPLive
AUGUST 8, 2024
Levels of obesity indicators, including body mass index and waist circumference, were notably higher in patients with gout compared to those without gout.
Obesity 52
52 
Childhood stress linked to higher risk of high blood pressure, obesity, diabetes in adults
Medical Xpress - Cardiology
JANUARY 17, 2024
Young adults who reported higher stress during their teenage years to adulthood were more likely to have high blood pressure, obesity and other cardiometabolic risk factors than their peers who reported less stress, according to new research published in the Journal of the American Heart Association.
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
The New England Journal of Medicine
NOVEMBER 10, 2023
In a trial in patients with cardiovascular disease and overweight or obesity but no diabetes, semaglutide was superior to placebo in lowering the risk of major adverse cardiovascular events at a mean follow-up of 39.8
Obesity 40
40 
Major CVD event risk cut by 20% in adults without diabetes, with overweight or obesity
American Heart News - Heart News
NOVEMBER 11, 2023
Research Highlights: In a large, international clinical trial, people with obesity or overweight but not diabetes taking semaglutide for more than 3 years had a 20% lower risk of heart attack, stroke or death due to cardiovascular disease and lost an.
Obesity 52
52 
How To Reverse Diabetes.
Dr. Paddy Barrett
MAY 24, 2024
In the US, over 45% of the population has either diabetes or pre-diabetes 1. The absolute majority of those with diabetes have type 2 diabetes, which is usually associated with excess visceral fat and poor cardiometabolic health. Because a diagnosis of diabetes is very likely to shorten your life. Pre-Diabetes.
Diabetes 89
89 
PO-06-026 OUTCOMES IN NON-OBESE HEART FAILURE PATIENTS WITH METABOLIC SYNDROME OR DIABETES
HeartRhythm
APRIL 30, 2024
However, the role of MS and diabetes in predicting HF outcomes was not assessed in non-obese patients. We have previously shown an association between metabolic syndrome (MS) and heart failure (HF) outcomes in patients with implanted defibrillators (ICD) and cardiac resynchronization therapy (CRT-D).
Roche Enters Obesity Arena with Carmot Acquisition
CardiacWire
DECEMBER 6, 2023
The already massive GLP-1 obesity drug segment might have gained a major future competitor last week, following Roche’s acquisition of weight loss biotech Carmot Therapeutics. The biotech also has a once-daily dual GLP-1/GIP injectable (yes, daily) that’s in Phase 2 trials and would treat obese or overweight patients with type 1 diabetes.
Obesity 59
59 
Semaglutide in Obesity-Related HFpEF: Pooled Analysis
American College of Cardiology
APRIL 10, 2024
What are the effects of semaglutide across a broad range of outcomes in people with obesity-related heart failure with preserved ejection fraction (HFpEF) with and without diabetes, and consistency across key patient subgroups?
Semaglutide found to cut major adverse cardiovascular events in people with overweight, obesity
Medical Xpress - Cardiology
JULY 9, 2024
Semaglutide reduces cardiovascular events, regardless of baseline glycated hemoglobin (HbA1c), among people with overweight or obesity and established atherosclerotic cardiovascular disease, according to a study published online June 22 in Diabetes Care.
Obesity 52
52 
Weight Cycling Linked to Fat-Free Mass Loss in People At Risk of Diabetes
HCPLive
DECEMBER 19, 2023
Weight cycling could lead to a relative loss of fat-free mass in people living with overweight and obesity at high risk of type 2 diabetes.
Diabetes 105
105 
Wegovy Helps HFpEF Patients With Diabetes Mellitus
Med Page Today
APRIL 7, 2024
(MedPage Today) -- ATLANTA -- Weight loss and heart failure benefits with semaglutide (Wegovy) extended to patients with obesity-related heart failure with preserved ejection fraction (HFpEF) who have type 2 diabetes, the STEP-HFpEF DM trial showed.
Challenges in the Cardiovascular Evaluation and Management of Patients With Obesity
American College of Cardiology
JANUARY 8, 2024
Obesity is a multifaceted disease that is directly and indirectly implicated in atherosclerotic cardiovascular disease (CVD), heart failure (HF), atrial fibrillation (AF), and multiple CVD risk factors, including dyslipidemia, hypertension, type 2 diabetes mellitus (DM), and sleep disorders.
Obesity 71
71 
Should We Reclassify Diabetes Subtypes?
HCPLive
MAY 22, 2024
Ji Hyun “CJ” Chun, MPAS, PA-C, BC-ADM, explains the potential value of defining diabetes subtypes based on insulin, obesity and age factors.
Diabetes 52
52 
The heart of the question: Who can get Medicare-covered weight loss medicine?
Science Daily - Heart Disease
SEPTEMBER 23, 2024
With Medicare now covering semaglutide for people with obesity and cardiovascular disease who don't have diabetes, a study looks at who that might include, depending on what cutoffs prescription plans apply.
Medicare 121
121 
STEP-HFpEF: Body Weight Reduction With Semaglutide Greater in Women Than Men With Obesity-Related HFpEF
American College of Cardiology
JUNE 24, 2024
Semaglutide reduces body weight to a greater extent in women with obesity-related heart failure with preserved ejection fraction (HFpEF) than in men, and improved Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS) to the same extent in both women and men, according to results from a prespecified secondary analysis of pooled (..)
More Data Support Semaglutide for Obesity-Related HFpEF, Regardless of Diabetes Diagnosis
NEJM Journal Watch - Cardiology
MAY 2, 2024
A pooled analysis from two harmonized, industry-funded trials shows improved obesity and symptoms and markers of HFpEF.
Obesity 45
45 Obesity indices and the risk of total and cardiovascular mortality among people with diabetes: a long-term follow-up study in Taiwan
Cardiovascular Diabetology
DECEMBER 12, 2023
The association between obesity indicators and mortality in individuals with diabetes remains unclear, and data on cardiovascular mortality are scarce. Therefore, we investigated the associations between the f.
Obesity 40
40 
GLP-1s reduce cardiovascular mortality: Study
Becker's Hospital Review - Cardiology
AUGUST 27, 2024
22 in Diabetes, Obesity and Metabolism: A Journal of Pharmacology and Therapeutics. GLP-1s reduced mortality and complications from cardiovascular events, according to a study published Aug.
Pharmacology 114
114 
STEP HFpEF DM: Semaglutide 2.4 mg Improves Functional Status, Symptoms in Patients with Diabetes, HFpEF
HCPLive
APRIL 6, 2024
24 shows significant improvements in symptoms among patients with obesity-related HFpEF and diabetes mellitus. The STEP HFpEF DM trial at ACC.24
Diabetes 59
59 
Weight change and risk of incident type 2 diabetes: short, medium and long-term follow-up in tehran lipid and glucose study
Cardiovascular Diabetology
JUNE 17, 2024
Despite the high burden of obesity and Type 2 diabetes (T2DM) in the Middle East/West Asia region, the effect of weight change on the development of T2DM is poorly addressed. Therefore, we aimed to assess the.
Diabetes 59
59 
Impact of Obesity on Atrial Fibrillation Pathogenesis and Treatment Options
Journal of the American Heart Association
DECEMBER 29, 2023
Obesity significantly increases AF risk, both directly and indirectly, through related conditions, like hypertension, diabetes, and heart failure. In particular, expanding epicardial adipose tissue during obesity has been suggested as a key driver of AF via paracrine signaling and direct infiltration.
Obesity 45
45 
Expert Perspective: The Obesity Paradox with Salvatore Carbone, PhD
Cardiometabolic Health Congress
JULY 25, 2023
Can you please explain the concept of an obesity paradox? Salvatore Carbone, PhD: First, I’d like to point out that obesity is a major risk factor for cardiometabolic disease. 2, 3] This association is more pronounced for those with class I obesity, which is a body mass index (BMI) between 30-35 kg/m2.
Obesity 52
52 
Liraglutide and not lifestyle intervention reduces soluble CD163 after comparable weight loss in obese participants with prediabetes or type 2 diabetes mellitus
Cardiovascular Diabetology
APRIL 28, 2024
The GLP-1 receptor agonist liraglutide is used to treat hyperglycemia in type 2 diabetes but is also known to induce weight loss, preserve the beta cell and reduce cardiovascular risk. The mechanisms underlyin.
Diabetes 64
64 
Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity
American College of Cardiology
DECEMBER 14, 2023
The goal of the SELECT trial was to determine the association of subcutaneous semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), with cardiovascular (CV) events in a secondary prevention cohort of patients with overweight or obesity and prior CV disease (CVD) without diabetes mellitus (DM).
Obesity 56
56 
Bariatric Surgery Linked With Lower Mortality vs GLP-1 Drugs in Study, but.
Med Page Today
JUNE 7, 2024
(MedPage Today) -- For people with obesity and diabetes, bariatric metabolic surgery was associated with a greater reduction in mortality compared with first-generation GLP-1 receptor agonists if the individuals had their diabetes for a decade.
Obesity 111
111 
Tirzepatide’s Prediabetes and Hypertension Impact
CardiacWire
AUGUST 23, 2024
It looks like we might be able to add prediabetes and hypertension to the growing list of conditions that Eli Lilly’s “weight loss drug” tirzepatide is able to treat, after new analysis of the SURMOUNT-1 trial showed significant reductions in blood pressure and diabetes progression. mm Hg systolic and 4.2 of placebo-takers.
Hypertension 64
64 
Effects of dietary interventions and intermittent fasting on HDL function in obese individuals with T2DM: a randomized controlled trial
Cardiovascular Diabetology
SEPTEMBER 11, 2024
Cardiovascular disease represents a significant risk factor for mortality in individuals with type 2 diabetes mellitus (T2DM). High-density lipoprotein (HDL) is believed to play a crucial role in maintaining c.
Obesity 83
83 
Compromised cardiac autonomic function in non-diabetic subjects with 1 h post-load hyperglycemia: a cross-sectional study
Cardiovascular Diabetology
AUGUST 9, 2024
A compromised cardiac autonomic function has been found in subjects with insulin resistance related disorders such as obesity, impaired glucose tolerance (IGT) and type 2 diabetes and confers an increased risk.
Diabetes 40
40 
Cardiovascular outcomes with exenatide in type 2 diabetes according to ejection fraction: The EXSCEL trial
European Journal of Heart Failure
OCTOBER 9, 2024
Cardiovascular outcomes with exenatide in type 2 diabetes (T2D) according to left ventricular ejection fraction (LVEF): the EXSCEL trial. Aims Glucagon-like peptide-1 receptor agonists reduce major adverse cardiovascular events (MACE) and cardiovascular mortality in people with type 2 diabetes (T2D).
Diabetes 40
40 Semaglutide Improves Outcomes in Patients with Obesity, HFpEF, and Type 2 Diabetes
NEJM Journal Watch - Cardiology
APRIL 7, 2024
In a randomized, controlled trial, semaglutide resulted in greater weight loss, improved symptoms, and fewer serious adverse events compared with placebo.
Obesity 72
72 
Let's personalize your content